Platelets: What, how much, for whom, does it matter?

Daniela Filipescu, MD, PhD, DEAA
Associate Professor of Anesthesia & Intensive Care Medicine
Department of Cardiac Anesthesia & Intensive Care Medicine
Emergency Institute for Cardiovascular Diseases
Bucharest, Romania
I received in the past travel grants and speaker fees from Bayer, GSK, Novo-Nordisk, Pfizer and Sanofi-Aventis

Co-author of 2013 European Guidelines on management of the trauma bleeding patients – unrestricted grant from CLS Behring and LFB France

Co-author of 2013 ESA Guidelines on management of the severe perioperative bleeding
- Anucleate, discoid circulating blood cells
- Derived from bone marrow megakaryocytes
- 1-2 μm diameter
- Mean volume 8 femtoliters (10^{-15}/L)
- Each liter of whole blood has 2 mL of platelets
- Total body platelet volume is 15 mL
- 1/3 of platelets are in the spleen
- Normal range in blood 150-400 x 10^9/L (150,000-400,000 ml^{-1})
- 10 % are produced daily

Random Donor Platelets (RDP) preparation from whole blood using a platelet rich plasma (PRP) or buffy coat (BC) intermediary

- BC RDP contain less plasma/leucocytes
- BC RDP are re-suspended in plasma or platelet additive solutions (PAS)
- 1 RDP unit contains: $1-1.5 \times 10^9$ platelets/ml
  $0.5 \times 10^{11}$ platelets

Katus MC et al. Vox Sanguinis 2014:103-113
What? Platelet products

- Single Donor Apheresis Platelets (SDAP)
- 1 apheresis unit contains $3 \times 10^{11}$ platelets ($> 2.4 \times 10^{11}$)

Holbro A et al. Swiss Med Weekly 2013:13885
Parker RI. Critical Care Med 2014: 675-690
What? Platelet products

RDP units
+ availability
- require pooling from 4-6/3-5 donors to obtain an adult dose
- increased donor exposure
- difficult matching
- increased risk of bacterial contamination?

SDAP
+ higher corrected count increments
+ selected donors can provide 2-3 doses within a single collection
- higher cost (equipment, technician labor)
- increased donation time
- increased rate of donor reactions

Same effectiveness in terms of bleeding prevention

Katus MC et al. Vox Sanguinis 2014:1-3-113
Holbro A et al. Swiss Med Weekly 2013:13885
Triulzi DJ et al. Blood 2012:5553-5562
What?
Storage of platelet products

Stored at 20-24°C Celsius
Constantly gently agitated
Shelf life 4-7 days
Infused in 30 mins

Quality indicators:
Visible swirl score
Morphology
pH
Lactate
Glucose concentration
Extent of shape change
CD62P expression

Stroncek DF & Rebulla P.
Lancet 2007:427-438

**What?**

**Bacterial contamination**

- **Incidence in platelet concentrates**
  - 1:5000 culture positive
  - 1:10,000 cause reactions
  - 1:10-25,000 cause sepsis
  - 1:40-75,000 cause mortality

- **Organisms involved**
  - Gram neg. rods, Gram pos. cocci

- **Sources**
  - Contaminated equipment, nonsterile procedure
  - Donor skin
  - Donor blood

O'Brien et al. Transfusion 2007:316-325
We recommend photochemical pathogen inactivation with amotosalen and UVA light for platelets.

1C
Pathogen reduced platelets for the prevention of bleeding

1422 patients included in 10 trials.

- No evidence of a difference in mortality, 'clinically significant' or 'severe bleeding', transfusion reactions or adverse events between pathogen-reduced and standard platelets.

- For a range of laboratory outcomes the results indicated evidence of some benefits for standard platelets over pathogen-reduced platelets.

Butler C et al. Cochrane Database Syst Rev 2013
What?
Platelet products

Special platelet products

- Male donors only
- “Fresh” platelets
- Leukodepleted
- Cryopreserved
- Washed
- Irradiated
We recommend that multiparous women be excluded from donating blood for the preparation of FFP and for the suspension of platelets in order to reduce the incidence of TRALI 1C.
White blood cell (WBC) alloimmunization may occur following previous exposure to WBCs through pregnancy or transfusion
- 332 female plateletpheresis donors
- 17% had detectable anti-HLA antibody
- Frequency of HLA antibodies increased with pregnancy:
  - 0 pregnancies: 7.8%
  - 1-2 pregnancies: 14.6%
  - 3 or more: 26.3%

Densmore et al. Transfusion 1999;39:103-6
TRALI: incidence

- 1:5,000-1:12,000 units
- 1:260,000 for all components
- FFP-1:22,500-1:66,000 units
- PLTs-0-1:420,000 units
- RBCs-1:82,500-1:2,860,000 units

French Hemovigilance Network 2007-2008
- 1:83,000 all blood products
- 1:31,000 units for FFP and apheresis PLTs
- no cases due to whole blood pooled PLTs


UK 2012: 11 suspected TRALI; no death

Katus MC et al. Vox Sanguinis 2014:1-3-113
Platelets secrete several hundreds biological response modifiers (BRM)
What?
TRALI: duration of storage

A

p value for trend: 0.17

Relative risk of TRALI
(reference is 15 to 21 days)

Storage time (days)

RBC

B

p value for trend: 0.44

Relative risk of TRALI
(reference is <266 days)

Storage time (days)

FFP

C

p value for trend: 0.036

Relative risk of TRALI
(reference is <4 days)

Storage time (days)

PLTs

Middelburg RA et al. Transfusion 2012;52:658
What?
Leuko-depleted platelets

Residual leucocytes
EU: $< 1 \times 10^6$ per unit in 90% of units
FDA: $< 5 \times 10^6$ per unit in 90% of units

Universal leukoreduction may reduce
- febrile reactions (FNHTR)
- platelet refractoriness due to HLA alloimunisation
- transmission of CMV

Holbro A et al. Swiss Med Weekly 2013:13885
Katus MC et al. Vox Sanguinis 2014:1-3-113
We recommend that labile blood components used for transfusion are leuko-depleted

1B

Kozek-Langenecker S et al. EJA 2013
How much? Platelet dose

• Platelet dose ($x \times 10^{11}$):
  Target platelet count increment $\times$ Blood volume $\times$ 1.5/100

• Traditional dose in onco-haematology
  – $0.07 \times 10^{11}$/kg for stable thrombocytopenic pts
  – $0.15 \times 10^{11}$/kg for acute platelet consumption
  Higher and lower doses are debated

1 Random donor platelet unit / 10 kg (6-8 RDPs)
1 Single Donor Apheresis Platelets (equivalent to 6-8 RDPs)

Holbro A et al. Swiss Med Weekly 2013:13885
How much?
Platelet dose

Assessment of platelet transfusion efficacy
- Clinical endpoints (bleeding)
- Absolute platelet increment (API): PLT post - PLT pre
  1 dose of platelets should raise patient’s counts by 30 x10^9/L in 1h
- Corrected count increment (CCI): API x body surface/ PLT dose
  >7.5 at 1h and > 4.5 at 24hrs
- Platelet recovery: API x blood volume/ PLT dose
  > 20% at 1h and > 10% at 24hrs

Holbro A et al. Swiss Med Weekly 2013:13885
How much?
Factors associated with refractoriness

**Product factors**
- Dose of platelet
- Storage time
- ABO mismatch
- Re-suspension in additive solutions vs. plasma
- Pathogen reduction
- Irradiation

**Patient factors**
- Clinical situation: fever, sepsis, splenomegaly, bleeding, DIC, GVHD
- Alloimmunization
- Drugs (IVIG, Ampho B, Vancomycin, Heparin, GPIIb/IIIa antagonists)

Holbro A et al. Swiss Med Weekly 2013:13885
How much?

Strategies to improve response to platelet transfusions

- Treat underlying condition
- Transfuse ABO identical platelets
- Transfuse platelets <48 hrs in storage
- Increase platelet dose
- Select HLA identical or compatible or permissive platelet product
For whom?
Prophylactic transfusion in patients with thrombocytopenia

Hemato-oncological patients
< 10,000 - 20,000/ mL (10-20 x 10⁹/L)
Increased threshold in uncontrolled hypertension, intracranial mass lesion, recent haemorrhage or surgery, recent gastrointestinal hemorrhage
Lower threshold (5-10 x 10⁹/L) is safe in chronic stable thrombocytopenia
Most of platelet transfusion do not conform guidelines

Prophylactic or no-prophylactic platelet transfusion was controversial in hemato-oncology
Recent studies support prophylactic platelet transfusion at 10 x 10⁹/L

Lieberman L et al. Blood 2014; 1146-1151
Holbro A et al. Swiss Med Weekly 2013:13885
Parker RI. Critical Care Med 2014: 675-690
For whom?
Prophylactic transfusion in patients with thrombocytopenia

Time to the primary outcome

---

For whom?
Prophylactic transfusion in patients with thrombocytopenia

Periprocedural
< 50 x $10^9$/L prior to invasive procedures (central venous catheter placement, bronchoscopy, endoscopy, solid organ biopsy)
< 100 x $10^9$/L CNS/eye/spinal procedures

Holbro A et al. Swiss Med Weekly 2013:13885
Parker RI. Critical Care Med 2014: 675-690
Is 50 $\times 10^9$/L a too high threshold?

No severe bleedings occurred in more than 600 central venous catheter insertions in patients with hematologic malignancies.

Moderate bleedings may occur at any PLT counts.
The risk of non severe bleeding was increased only in patients with PLT counts below 20 $\times 10^9$/L, but not with PLT counts between 20 $\times 10^9$/L and 49 $\times 10^9$/L.

Thus, only patients with PLT counts below 20 $\times 10^9$/L should receive preprocedural PLT transfusions.

Strict adherence to this transfusion policy could save approximately 40% of all PLT transfusions before CVC insertions.

Zeidler K et al. Transfusion 2011:2269-2276
For whom?
Therapeutic transfusion

Platelet transfusions for active bleeding are much more common on surgical and cardiology services.

Stop bleeding in patients with:
- thrombocytopenia $< 50 \times 10^9$ /L
- drug induced platelet dysfunctions
- trauma and massive transfusion

Lieberman L et al. Blood 2014; 1146-1151
Holbro A et al. Swiss Med Weekly 2013:13885
For whom?
Traditional way of replacement therapy in severe bleeding

Hemostatic Factors and Replacement of Major Blood Loss with Plasma-Poor Red Cell Concentrates

Seppo T. Hiippala, MD, Gunnar J. Myllylä, MD, and Elina M. Vahtera, PhD

Department of Anesthesiology, Helsinki University Central Hospital, and Finnish Red Cross Blood Transfusion Service, Helsinki, Finland

Anesth Analg 1995;81:360-5

Critical level of hemostatic factors and the inversely predicted corresponding blood loss (95% confidence interval) as percent of calculated blood volume

<table>
<thead>
<tr>
<th>Hemostatic factor</th>
<th>Critical level</th>
<th>Blood loss (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelets</td>
<td>50 x 10³ / mm³</td>
<td>230 (169-294)</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>1.0 g / L</td>
<td>142 (117-169)</td>
</tr>
<tr>
<td>Prothrombin</td>
<td>20</td>
<td>201 (160-244)</td>
</tr>
<tr>
<td>Factor V</td>
<td>25</td>
<td>229 (167-300)</td>
</tr>
<tr>
<td>Factor VII</td>
<td>20</td>
<td>236 (198-277)</td>
</tr>
</tbody>
</table>
For whom?
Therapeutic approach

Görlinger, 2012

- rFVIIa
- FXIII
- Platelets
- 4F-PCC (or FFP)
- Fibrinogen (or Cryo)
- Antifibrinolytics
- Aspirin? Oral anticoagulants? Heparin?
- Basic conditions
  \( T_C > 34^\circ C; \ pH > 7.2; \ \text{Ca}_i > 1 \text{ mmol/l}; \ \text{Hb} > 8 \text{ g/L} \)
- Surgical stanching
  (Compression bandage; pelvic compression; packing)
Algorithm in bleeding patients based on conventional coagulation and ROTEM parameters.
For whom?
Thrombocytopenia in ICU

Platelet count < $150 \times 10^9$/L

Incidence: 8.3-67.6% on admission in ICU
13-44% acquired during ICU stay in adults

Causes: infection, inflammation, coagulation factor consumption

Treatment: 9-30% receive platelet transfusion

Associated with bleeding
Independent predictor of mortality
Lack of evidence for benefit from platelet transfusion

Lauzier F et al Intensive Care Med 2013:2135-2143
For whom?
Platelet transfusion for thrombocytopenia in ICU

Platelet count increment
sustained correction rarely achieved
median increase $15 \times 10^9$/L

Bleeding
no report on bleeding avoidance with platelet transfusion

Mortality
Insufficient evidence

For critically ill adults with severe thrombocytopenia and no evidence of bleeding there is insufficient evidence to make a recommendation for or against platelet transfusion

Lieberman L et al. Blood 2014; 1146-1151
For whom?
Platelet transfusion indications in sepsis

In patients with severe sepsis, we suggest that platelets be administered prophylactically when counts are \( \leq 10,000/\text{mm}^3 \) (10 \( \times \) \( 10^9 \)/L) in the absence of apparent bleeding, as well when counts are \( \leq 20,000/\text{mm}^3 \) (20 \( \times \) \( 10^9 \)/L) if the patient has a significant risk of bleeding. Higher platelet counts (\( \geq 50,000/\text{mm}^3 \) [50 \( \times \) \( 10^9 \)/L]) are advised for active bleeding, surgery, or invasive procedures (grade 2D).

Dellinger P et al. Intensive Care Med 2013; 165-228
Does it matter?
The “cell based model” of coagulation

Does it matter?
Efficacy of platelet transfusion

Table 1. Results of the Analyses Performed Before and After Platelet Transfusions

<table>
<thead>
<tr>
<th></th>
<th>Before Transfusion</th>
<th>After Transfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb (g/L)</td>
<td>91 (88–101)</td>
<td>88.5 (83–94)</td>
</tr>
<tr>
<td>PT (INR)</td>
<td>1.2 (0.9–1.4)</td>
<td>1.2 (0.9–1.3)</td>
</tr>
<tr>
<td>aPTT (s)</td>
<td>35.5 (27–54)</td>
<td>37 (27–61)</td>
</tr>
<tr>
<td>Platelet count (×10⁹/L)</td>
<td>31.5 (20–44)</td>
<td>43.5 (38–71)*</td>
</tr>
<tr>
<td>Clotting time (s)</td>
<td>103.5 (81–215)</td>
<td>108.5 (51–158)</td>
</tr>
<tr>
<td>Clot formation time (s)</td>
<td>181.5 (108–347)</td>
<td>123 (89–233)*</td>
</tr>
<tr>
<td>Maximum clot firmness (mm)</td>
<td>42 (38–50)</td>
<td>51.5 (45–56)*</td>
</tr>
<tr>
<td>G (dynes/cm²)</td>
<td>3623 (2353–6111)</td>
<td>5319 (3333–7500)*</td>
</tr>
</tbody>
</table>

PT = prothrombin time; aPTT = activated partial thromboplastin time; Hb = hemoglobin.
* P = 0.005, when compared with before transfusion.

26 Patients with variceal ligations
Thrombocytopenia < 50,000/ml
1 adult standard dose

Results:
Slightly increase in platelet count
Thrombin generation marginally improved
Vascoeleastic tests improved statistically but not clinically significant
Does it matter?
Platelet function assay before and after platelet transfusion platelet

Does it matter?
Trauma

How would you transfuse (resuscitate) this type of casualty?
War as a laboratory for trauma research
Current US Army Policy

- Transfuse to a ratio of 1:1:1 of FFP:RBC:PLT for those patients presenting with
  - severe life threatening trauma/hemorrhage
  - at risk for massive transfusion
- Use of fresh whole blood is authorized for patients with life-threatening injuries (at discretion of MD)
More plasma & platelets, better outcome...

Survival to 30 days

Logrank p < 0.001

High FFP and Plt
Low FFP and high Plt
High FFP and low Plt
Low FFP and Plt

Increased Platelet:RBC Ratios Are Associated With Improved Survival After Massive Transfusion

John B. Holcomb, MD, FACS, Lee A. Zarzabal, MS, Joel E. Michalek, PhD, Rosemary A. Kozar, MD, PhD, Phillip C. Spinella, MD, FCCM, Jeremy G. Perkins, MD, Nena Matijevic, PhD, Jing-Fei Dong, MD, PhD, Shibani Pati, MD, PhD, Charles E. Wade, PhD, and the Trauma Outcomes Group

TABLE 7. Propensity Score Adjusted Multivariate Cox Regressions: Variables Associated With 24-Hour and 30-Day Mortality Comparison to Reference (High)

<table>
<thead>
<tr>
<th>Variable</th>
<th>24-Hour Survival</th>
<th></th>
<th>30-Day Survival</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>p*</td>
<td>RR (95% CI)</td>
<td>p*</td>
</tr>
<tr>
<td>Platelet:RBC ratio Grp (low vs high)</td>
<td>2.81 (1.36–5.8)</td>
<td>0.005</td>
<td>1.77 (1.16–2.68)</td>
<td>0.007</td>
</tr>
<tr>
<td>Platelet:RBC ratio Grp (med vs high)</td>
<td>3.13 (1.52–6.45)</td>
<td>0.002</td>
<td>1.75 (1.15–2.65)</td>
<td>0.008</td>
</tr>
<tr>
<td>ISS</td>
<td>1.03 (1.02–1.05)</td>
<td>&lt;0.001</td>
<td>1.04 (1.03–1.05)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Admission deficit</td>
<td>0.91 (0.87–0.95)</td>
<td>&lt;0.001</td>
<td>0.95 (0.92–0.97)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FFP:RBC ratio</td>
<td>0.15 (0.06–0.42)</td>
<td>&lt;0.001</td>
<td>0.49 (0.28–0.86)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

* p from χ² test.
Survivorship bias

“As component blood products are not administered uniformly and simultaneously in civilian clinical practice, and many deaths occur early, it is possible that the survival advantage observed among those receiving a higher FFP:PRBC ratio may simply reflect the fact that they lived long enough to receive the higher ratio of products.”

Snyder et al, J Trauma 66:358-364, 2009
Does it matter?
Trauma patients

Summary of mortality outcomes according to survival bias

# Does it matter? Trauma patients

Early coagulopathy in trauma patients: An on-scene and hospital admission study

*Bernard Floccard*, *Lucia Rugeri*, *Alexandre Faure*, *Marc Saint Denis*, *Eileen Mary Boyle*, *Olivier Peguet*, *Albrice Levrat*, *Christian Guillaume*, *Guillaume Marcotte*, *Alexandre Vulliez*, *Etienne Hautin*, *Jean Stéphane David*, *Claude Négrier*, *Bernard Allaouchiche*

---

<table>
<thead>
<tr>
<th>Injury severity score ranges and coagulation parameters on admission.</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 &lt; ISS &lt; 14 (n=12)</td>
</tr>
<tr>
<td>----------------------</td>
</tr>
<tr>
<td>aPTT (s)</td>
</tr>
<tr>
<td>Prothrombin time (s)</td>
</tr>
<tr>
<td>INR</td>
</tr>
<tr>
<td>Fibrinogen (g/L)</td>
</tr>
<tr>
<td>Factor II (UI/mL)</td>
</tr>
<tr>
<td>Factor V (UI/mL)</td>
</tr>
<tr>
<td>FDP (µg/mL)</td>
</tr>
<tr>
<td>PC (UI/mL)</td>
</tr>
<tr>
<td>AT (UI/mL)</td>
</tr>
<tr>
<td>Platelets (10⁹/L)</td>
</tr>
<tr>
<td>Haemoglobin (g/L)</td>
</tr>
<tr>
<td>AIS head</td>
</tr>
<tr>
<td>Volume fluid administration (mL)</td>
</tr>
</tbody>
</table>

Injury 2012: 26–32
Probability of death at 24 hours by admission platelet count. Unadjusted logistic regression model includes admission platelet count.
Early Platelet Dysfunction: An Unrecognized Role in the Acute Coagulopathy of Trauma

Max V. Wohlauer, MD, Ernest E. Moore, MD, FACS, Scott Thomas, MD, FACS, Angela Sauraia, MD, PhD, Ed Evans, BA, CCP, Jeffrey Harr, MD, MPH, Christopher C. Silliman, MD, PhD, Victoria Ploplis, PhD, Francis J. Castellino, PhD, and Mark Walsh, MD.
Does it matter?
Traumatic brain injury

Independent risk factors for death in patients with severe TBI

<table>
<thead>
<tr>
<th>Independent Variables</th>
<th>OR (CI 95%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISS ≥25</td>
<td>10.75 (2.78–41.67)</td>
<td>0.001</td>
</tr>
<tr>
<td>AIS head 4 or 5</td>
<td>10.31 (2.36–45.45)</td>
<td>0.002</td>
</tr>
<tr>
<td>Platelet &lt;100,000/mm³ at admission</td>
<td>9.52 (1.26–71.43)</td>
<td>0.029</td>
</tr>
<tr>
<td>aPTT ≥36 s at admission</td>
<td>9.09 (2.82–29.41)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age ≥55</td>
<td>5.08 (2.02–12.82)</td>
<td>0.001</td>
</tr>
<tr>
<td>GCS score ≤8 at admission</td>
<td>2.59 (1.08–6.21)</td>
<td>0.033</td>
</tr>
<tr>
<td>INR ≥1.2 at admission</td>
<td>2.49 (1.08–5.78)</td>
<td>0.033</td>
</tr>
</tbody>
</table>

Schnüriger et al. Journal of Trauma and Acute Care Surgery 2010; 68(4):881-885
Kaplan-Meier curves for the ≥ 10 units RBC in 24-hour groups
Management of bleeding and coagulopathy following major trauma: An updated European guideline

We recommend that platelets be administered to maintain a platelet count above $50 \times 10^9/l$.  

Grade 1C

We suggest maintenance of a platelet count above $100 \times 10^9/l$ in patients with ongoing bleeding and/or TBI.  

Grade 2C

We suggest an initial dose of 4-8 single platelet units or one aphaeresis pack. 

Grade 2C

Spahn D et al. Crit Care 2013;17:R76
Doest it matter?
Patients on antiplatelet agents

Aspirin, clopidogrel, prasurgel, ticagrelor, Oh My!
For intra- or postoperative bleeding clearly related to aspirin, we suggest that platelet transfusion be considered (dose: $0.7 \times 10^{11}$ [i.e. two standard concentrates] per 7 kg body weight in adults).

2C

We suggest that platelet transfusion be considered (dose: $0.7 \times 10^{11}$ [i.e., two standard concentrates] per 7 kg body weight in adults) in cases of intra- or postoperative bleeding clearly related to clopidogrel or prasugrel

2C
Normalization of platelet reactivity in clopidogrel-treated subjects

G. Vilahur,*1 B. G. Choi,*1 M. U. Zafar,* J. F. Viles-Gonzalez,* D. A. Vorchheimer,†
V. Fuster† and J. J. Badimon*†
*Cardiovascular Biology Research Laboratory; and †Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, USA

Journal of Thrombosis and Haemostasis, 5: 82–90

Table 2  Dose conversion table of % pooled volunteers (V)-platelet rich plasma (PRP) to number of platelet units or pools. The mean platelet count of the 11 subjects participating in the study serves as example (250 × 10^6 platelets per μL).

<table>
<thead>
<tr>
<th>% Added pooled V-PRP</th>
<th>Platelet units*</th>
<th>Platelet pools†</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>40</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>50</td>
<td>12.5</td>
<td>2–3</td>
</tr>
<tr>
<td>60</td>
<td>15</td>
<td>3</td>
</tr>
</tbody>
</table>

*Platelet units: one platelet unit increases platelet count by 10 000 μL.
†Platelet pools: five platelet units = one platelet pool.
Does it matter?
Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery

Thiele T. Journal of Thrombosis and Haemostasis 2012: 968-971
Does it matter?

Intracranial Hemorrhage (Traumatic or Spontaneous)

Aspirin alone
- Transfuse 5 units of platelets

Any thienopyridine
- Small ICH: Transfuse 10 units of platelets
- Large ICH: Initially DDAVP + 10 Units of platelets; Then 10 Units platelets q12h for 48h
A meta-analysis to determine the effect on survival of platelet transfusions in patients with either spontaneous or traumatic antiplatelet medication-associated intracranial haemorrhage

John S Batchelor, Alan Grayson

Key messages

- Six studies were found to be suitable for the meta-analysis (two studies for spontaneous ICH and the remaining four were traumatic intracranial haemorrhage).

- The pooled OR showed no benefit in survival following a platelet transfusion (OR=0.773, 95% CI 0.414 to 1.442).
Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: A systematic review

Daniel K. Nishijima, MD, MAS, Shahriar Zehtabchi, MD, Jeanette Berrong, DO, MPH, and Eric Legome, MD, Sacramento, California

CONCLUSION

Five retrospective registry studies with suboptimal methodologies provide inadequate evidence to support the routine use of platelet transfusion in adult emergency department patients with preinjury antiplatelet use and tICH.
Management of bleeding and coagulopathy following major trauma: An updated European guideline

We suggest the measurement of platelet function in patients treated or suspected of being treated with antiplatelet agents.

Grade 2C

If platelet dysfunction is documented in a patient with continued microvascular bleeding, we suggest treatment with platelet concentrates.

Grade 2C

We suggest administration of platelets in patients with substantial bleeding or intracranial haemorrhage who have been treated with antiplatelet agents.

Grade 2C
Does it matter?
Safety of platelet transfusion

- 1 adverse effect in every 1030 platelet transfusion
- Bacterial contamination 127-1886 per 1,000,000 cultures
- Febrile non-haemolytic transfusion reactions (FNHTR) 0.09 - 27%
- Allo immunization - 15% of chronic recipients
- Acute haemolytic reactions
  - 10-40% of platelet transfusions are incompatible
- Transfusion related acute lung injury (TRALI)
- Transfusion associated circulatory overload (TACO)
- Allergic reactions 0.09-21%
- Transfusion –associated graft-versus-host disease (TA-GVHD)

Holbro A et al. Swiss Med Weekly 2013:13885
Katus MC et al. Vox Sanguinis 2014:1-3-113
Adda R et al. ANSM 2012
Does it matter?
Strategies to reduce adverse events

• Use of only ABO-type specific platelets
• Use of plasma compatible platelets (screen the plasma for anti A and anti B antibodies)
• Limitation of quantity of incompatible plasma over time
• Component volume reduction (hyperconcentrated units)
• Resuspension of platelet component in PAS or AB plasma
• Washed platelets resuspended in electrolyte solutions
• Irradiation
• Synthetic analogues
• Alternatives

Katus MC et al. Vox Sanguinis 2014:1-3-113
“The true mystery of the world is in visible, not the invisible”

Oscar Wilde, The portrait of Dorian Grey
Conclusions

- Maintain platelet count > 100 000 x 10⁹/l in ongoing bleeding
- Transfuse platelets if < 50 000 x 10⁹/l if there is risk of bleeding
- Up-front platelet transfusion in predefined ratios has inadequate evidences
- Have a local protocol!
Does it matter?
Alternatives?

• Potential antiplatelet reversal therapies besides platelet transfusion include
  – Desmopressin
  – Recombinant activated coagulation factor VII (rFVIIa)
  – Tranexamic acid
  – Fibrinogen
Desmopressin
Efficacy in primary haemostasis

Recommendation 30
Desmopressin

We suggest that desmopressin (0.3 µg/kg) be administered in patients treated with platelet-inhibiting drugs or with von Willebrand disease.

Grade 2C
Spahn D et al. Crit Care 2013;17;36

We do not suggest that desmopressin be used routinely in the bleeding trauma patient.

Grade 2C
Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy


Eur J Anesthesiol 2011:57-62
Effect of platelet count on clot strength in EXTEM. Clot strength is given in maximum clot elasticity (MCE).

Prescribing blood: a checklist for clinicians

Always ask yourself the following questions before prescribing blood or blood products for a patient

1. What improvement in the patient's clinical condition am I aiming to achieve?

2. Can I minimize blood loss to reduce this patient's need for transfusion?

3. Are there any other treatments I should give before making the decision to transfuse, such as intravenous replacement fluids or oxygen?

4. What are the specific clinical or laboratory indications for transfusion for this patient?

5. What are the risks of transmitting HIV, hepatitis, syphilis or other infectious agents through the blood products that are available for this patient?

6. Do the benefits of transfusion outweigh the risks for this particular patient?

7. What other options are there if no blood is available in time?

8. Will a trained person monitor this patient and respond immediately if any acute transfusion reactions occur?

9. Have I recorded my decision and reasons for transfusion on the patient's chart and the blood request form?

Finally, if in doubt, ask yourself the following question.

10. If this blood was for myself or my child, would I accept the transfusion in these circumstances?